BlackRock Institutional Trust’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

BlackRock Institutional Trust’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$231K	Hold	80,368	–	–	﹤0.01%	3572
2016 Q3	$473K	Hold	80,368	–	–	﹤0.01%	3495
2016 Q2	$241K	Sell	80,368 -107,312	-57%	-$441K	﹤0.01%	3611
2016 Q1	$1.01M	Sell	187,680 -3,143	-2%	-$19.8K	﹤0.01%	3284
2015 Q4	$2.27M	Buy	190,823 +21,394	+13%	+$245K	﹤0.01%	3069
2015 Q3	$1.39M	Buy	169,429 +70,207	+71%	+$811K	﹤0.01%	3227
2015 Q2	$1.38M	Buy	99,222 +66,326	+202%	+$1.22M	﹤0.01%	3252
2015 Q1	$790K	Buy	32,896 +2,523	+8%	+$56.7K	﹤0.01%	3409
2014 Q4	$500K	Buy	30,373 +18	+0.1%	+$208	﹤0.01%	3497
2014 Q3	$386K	Sell	30,355 -27,014	-47%	-$407K	﹤0.01%	3531
2014 Q2	$1.29M	Sell	57,369 -2,174	-4%	-$39.4K	﹤0.01%	3358
2014 Q1	$1.68M	Buy	+59,543	New	+$2.21M	﹤0.01%	3230

Other funds holding DRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BlackRock Institutional Trust's DRNA Position: Q4 2016 in Review

BlackRock Institutional Trust held its Dicerna Pharmaceuticals, Inc. (DRNA) position steady in Q4 2016 at 80,368 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #3572.

BlackRock Institutional Trust first reported a position in DRNA in Q1 2014 and has held it in 12 quarters since. The position peaked at $2.27M in Q4 2015. 50 funds tracked by Wall St. Rank hold DRNA as of Q4 2016.

BlackRock Institutional Trust held 80,368 shares of Dicerna Pharmaceuticals, Inc. worth $231K as of Q4 2016.
BlackRock Institutional Trust left its Dicerna Pharmaceuticals, Inc. share count unchanged in Q4 2016.
Dicerna Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3572 holding.
BlackRock Institutional Trust first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2014 and has held it in 12 quarters since.
BlackRock Institutional Trust's Dicerna Pharmaceuticals, Inc. position peaked at $2.27M in Q4 2015.
50 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.